Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PONIF$0.12-0.00(-3.70%)Silver Pony Announces Closing of Up-Sized $1,600,015 Strategic Unit Offering[6:15:00 PM ET]ELME$0.07-1.70(-96.19%)Elme Communities Announces Suspended NYSE Trading; Anticipates Trading Will Begin OTC Effective October 26, 2026[5:47:00 PM ET]HHH$72.57+3.08(+4.43%)Howard Hughes Holdings Set to Join S&P SmallCap 600 Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on...[5:45:00 PM ET]ALGRF$0.400.00(0.00%)Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita[5:30:00 PM ET]ZEFIF$0.45+0.02(+3.56%)Zefiro Announces Closing of Non-Brokered Private Placement for Gross Proceeds of Approximately C$5.0 Million[5:29:00 PM ET]BLK$1,118.50-18.79(-1.65%)BlackRock® Canada Announces the Termination of iShares Convertible Bond Index ETF[5:23:34 PM ET]ITFS$1.43-0.02(-1.10%)Itafos Announces Release Date for Q3 2026 Results and Business Update Webcast[5:15:00 PM ET]FAGI$0.01-0.00(-13.33%)Full Alliance Group, Inc (OTC:FAGI) YAHBEE Highlights Community-Commerce Model for Agentic Commerce Era[5:15:00 PM ET]TGT$152.76-5.35(-3.38%)Vital Farms Introduces a Higher Standard for Free-Range Eggs Through Limited Pilot at Select Target Retail Stores[5:05:00 PM ET]NU$15.23+0.50(+3.39%)Notice to Market: Nu Holdings Ltd.[5:03:00 PM ET]POR$44.55-0.35(-0.78%)Portland General Electric Declares Dividend[5:00:00 PM ET]ANTX$3.55-0.09(-2.47%)AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)[5:00:00 PM ET]

VRTX · NASDAQ

Vertex Pharmaceuticals Incorporated

$523.93 -10.81 (-2.02%)

Company overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene, and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$133B
Employees
6,100
Headquarters
Boston, MA
Website
vrtx.com
CEO
Reshma Kewalramani
Listed
July 24, 1991
P/E
30.80
Dividend yield
0.00%

Company financials

Revenue
$12.3B
Gross profit
$10.6B
Operating income
$4.8B
EBITDA
$5.2B
Net income
$4.3B
EPS
$17.01
Total assets
$26.5B
Total debt
$2B
Gross margin
86.28%
Net margin
35.40%
Earnings yield
3.25%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

406.35446.31486.26526.21566.17
VRTX 1D NASDAQ O527.18H537.81L521.30C535.17+10.65 (+2.03%)Vol1.64M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
VRTX Press release Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 Business Wire
VRTX Press release Vortex Energy Receives Government Approval for Ground Gravity Survey at Robinsons River Salt Project GlobeNewswire
VRTX Stock news Where Will CRISPR Therapeutics Stock Be in 2030? The Motley Fool
VRTX Stock news Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. The Motley Fool
VRTX Stock news 3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA Defense World
VRTX Stock news Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? Zacks Investment Research
VRTX Stock news Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts Zacks Investment Research
VRTX Press release Vortex Energy Corp. Announces Extension of Marketing Program GlobeNewswire
VRTX Stock news Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders The Motley Fool
VRTX Stock news Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
VRTX Stock news Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference GuruFocus
VRTX Press release Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference Business Wire
VRTX Press release Vertex to Announce Third Quarter 2026 Financial Results November 2nd Business Wire
VRTX Stock news Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know Zacks Investment Research
VRTX Stock news Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know Zacks Investment Research
VRTX Stock news Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know Zacks Investment Research
VRTX Stock news Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It Zacks Investment Research
VRTX Stock news Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why Zacks Investment Research
VRTX Stock news Baird Financial Group Inc. Has $2.05 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX Defense World
VRTX Stock news Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
See more
FAQ

Questions about Vertex Pharmaceuticals Incorporated

What does Vertex Pharmaceuticals Incorporated do?
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene, and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
What is VRTX's market cap?
Vertex Pharmaceuticals Incorporated (VRTX) is a listed stock with a live quote. The latest market cap on this page is $133B.
Where is Vertex Pharmaceuticals Incorporated headquartered?
Vertex Pharmaceuticals Incorporated is headquartered in Boston, MA.
How do I get VRTX news from the API?
Call GET /v1/news?tickers=VRTX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does VRTX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for VRTX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the VRTX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs